论文部分内容阅读
事实上影响每个老年男子的良性前列腺增生(BPH)至今仍无药物疗法。但最近报告了预防增生甚至抑制增生的值得注意的实验结果。由新泽西州默克研究所正在研究的这类药物是5-α还原酶抑制剂,其目的在于减少双氢睾丸酮(DHT)的聚集。约翰斯·霍普金斯医学研究所泌尿学系主任Patrick C Walsh形容过置的DHT是BPH的标志。 Walsh在美国国立关节炎、糖尿病、消化道和肾病研究所举行的报告会上称,根据目前所知,有理由推测减少前列腺中DHT的浓度可以逆转本病。 Walsh说,用阻断睾丸素转变为DHT的
BPH, which actually affects every older man, is still no drug therapy. However, notable experimental results have recently been reported for preventing proliferation and even inhibiting proliferation. The class of drugs being studied by the Merck Institute in New Jersey is a 5-alpha reductase inhibitor with the goal of reducing the accumulation of dihydrotestosterone (DHT). Patrick C Walsh, director of the Department of Urology at Johns Hopkins Medical Institute, described the DHT as a hallmark of BPH. Walsh at the National Institute of Arthritis, Diabetes, Gastroenterology and Nephrology report held at the meeting, according to the current knowledge, there is reason to speculate that reducing the concentration of DHT in the prostate can reverse the disease. Walsh said that blocking testosterone into DHT